Cell line
|
Lung cell type
|
Paclitaxel (μM)
|
DN (μM)
|
---|
GI50
|
TGI
|
LC50
|
GI50
|
TGI
|
LC50
|
---|
MRC-5
|
Normal lung fibroblast
|
0.016 ± 0.005
|
0.297 ± 0.008
|
>32
|
11.4 ± 1.3
|
19.6 ± 0.7
|
>32
|
|
3 subtypes of NSCLC
| | | | | | |
A549
|
Adenocarcinoma
|
0.016 ± 0.001
|
0.058 ± 0.012
|
2.800 ± 0.400a
|
6.2 ± 0.7a
|
10.3 ± 0.3a
|
15.7 ± 1.3a
|
NCI-H226
|
Squamous cell carcinoma
|
0.017 ± 0.001
|
4.898 ± 0.480a
|
20.672 ± 0.436a
|
5.7 ± 1.2a
|
9.8 ± 0.3a
|
13.6 ± 1.2a
|
COR-L23
|
Large cell carcinoma
|
0.017 ± 0.001
|
3.450 ± 0.167a
|
17.725 ± 0.084a
|
3.7 ± 0.9a
|
8.0 ± 1.4a
|
18.9 ± 2.5a
|
NCI-1688
|
SCLC
|
0.012 ± 0.001
|
20.560 ± 0.147a
|
>32
|
15.2 ± 2.1
|
21.1 ± 2.4
|
>32
|
- DN concentrations required for 50% growth inhibition (GI50), total growth inhibition (TGI), and 50% decrease in cell numbers (LC50) relative to the untreated cells as measured by the SRB assay. Data are presented as the mean ± SD of at least 3 independent experiments.
-
aStatistical significance (p <0.05) versus MRC-5.